Type I interferon-mediated tumor immunity and its role in immunotherapy

被引：196

作者：

Yu, Renren ^{[1
,2
]}

Zhu, Bo ^{[1
,3
]}

Chen, Degao ^{[1
]}

机构：

[1] Third Mil Med Univ, Inst Canc, Xinqiao Hosp, Chongqing 400037, Peoples R China

[2] Wenzhou Med Univ, Affiliated Hosp 1, Dept Oncol, Wenzhou 325000, Peoples R China

[3] Third Mil Med Univ, Xinqiao Hosp, Chongqing Key Lab Immunotherapy, Chongqing 400037, Peoples R China

来源：

CELLULAR AND MOLECULAR LIFE SCIENCES | 2022年 / 79卷 / 03期

基金：

中国国家自然科学基金;

关键词：

IFN-alpha; IFN-beta; Tumor immunity; cGAS; STING; Radiation therapy; Oncolytic virotherapy; REGULATORY T-CELLS; CYCLIC GMP-AMP; ANTITUMOR IMMUNITY; PD-1; BLOCKADE; STING PATHWAY; IFN; CANCER; DNA; ALPHA; RESPONSES;

D O I：

10.1007/s00018-022-04219-z

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.

引用

页数：24

共 166 条

[41] Oncolytic virus-derived type I interferon restricts CAR T cell therapy [J].

Evgin, Laura ;

Huff, Amanda L. ;

Wongthida, Phonphimon ;

Thompson, Jill ;

Kottke, Tim ;

Tonne, Jason ;

Schuelke, Matthew ;

Ayasoufi, Katayoun ;

Driscoll, Christopher B. ;

Shim, Kevin G. ;

Reynolds, Pierce ;

Monie, Dileep D. ;

Johnson, Aaron J. ;

Coffey, Matt ;

Young, Sarah L. ;

Archer, Gary ;

Sampson, John ;

Pulido, Jose ;

Perez, Luis Sanchez ;

Vile, Richard .

NATURE COMMUNICATIONS, 2020, 11 (01)

[42] Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy [J].

Fend, Laetitia ;

Yamazaki, Takahiro ;

Remy, Christelle ;

Fahrner, Catherine ;

Gantzer, Murielle ;

Nourtier, Virginie ;

Preville, Xavier ;

Quemeneur, Eric ;

Kepp, Oliver ;

Adam, Julien ;

Marabelle, Aurelien ;

Pitt, Jonathan M. ;

Kroemer, Guido ;

Zitvogel, Laurence .

CANCER RESEARCH, 2017, 77 (15) :4146-4157

[43] ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways [J].

Feng, Xu ;

Tubbs, Anthony ;

Zhang, Chunchao ;

Tang, Mengfan ;

Sridharan, Sriram ;

Wang, Chao ;

Jiang, Dadi ;

Su, Dan ;

Zhang, Huimin ;

Chen, Zhen ;

Nie, Litong ;

Xiong, Yun ;

Huang, Min ;

Nussenzweig, Andre ;

Chen, Junjie .

EMBO JOURNAL, 2020, 39 (14)

[44]

Ferris RL, 2014, J CLIN ONCOL, V32

[45] INDUCERS OF INTERFERON AND HOST RESISTANCE .2. MULTISTRANDED SYNTHETIC POLYNUCLEOTIDE COMPLEXES [J].

FIELD, AK ;

TYTELL, AA ;

LAMPSON, GP ;

HILLEMAN, MR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1967, 58 (03) :1004-&

[46] In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma [J].

Frank, Matthew J. ;

Reagan, Patrick M. ;

Bartlett, Nancy L. ;

Gordon, Leo, I ;

Friedberg, Jonathan W. ;

Czerwinski, Debra K. ;

Long, Steven R. ;

Hoppe, Richard T. ;

Janssen, Robert ;

Candia, Albert F. ;

Coffman, Robert L. ;

Levy, Ronald .

CANCER DISCOVERY, 2018, 8 (10) :1258-1269

[47] Trial Watch: experimental TLR7/TLR8 agonists for oncological indications [J].

Frega, Giorgio ;

Wu, Qi ;

Le Naour, Julie ;

Vacchelli, Erika ;

Galluzzi, Lorenzo ;

Kroemer, Guido ;

Kepp, Oliver .

ONCOIMMUNOLOGY, 2020, 9 (01)

[48] STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade [J].

Fu, Juan ;

Kanne, David B. ;

Leong, Meredith ;

Glickman, Laura Hix ;

McWhirter, Sarah M. ;

Lemmens, Edward ;

Mechette, Ken ;

Leong, Justin J. ;

Lauer, Peter ;

Liu, Weiqun ;

Sivick, Kelsey E. ;

Zeng, Qi ;

Soares, Kevin C. ;

Zheng, Lei ;

Portnoy, Daniel A. ;

Woodward, Joshua J. ;

Pardoll, Drew M. ;

Dubensky, Thomas W., Jr. ;

Kim, Young .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (283)

[49] Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells [J].

Fuertes, Mercedes B. ;

Kacha, Aalok K. ;

Kline, Justin ;

Woo, Seng-Ryong ;

Kranz, David M. ;

Murphy, Kenneth M. ;

Gajewski, Thomas F. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (10) :2005-2016

[50] Cyclic [G(2′,5′) pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase [J].

Gao, Pu ;

Ascano, Manuel ;

Wu, Yang ;

Barchet, Winfried ;

Gaffney, Barbara L. ;

Zillinger, Thomas ;

Serganov, Artem A. ;

Liu, Yizhou ;

Jones, Roger A. ;

Hartmann, Gunther ;

Tuschl, Thomas ;

Patel, Dinshaw J. .

CELL, 2013, 153 (05) :1094-1107

← 1 2 3 4 5 6 7 8 9 10 →